Multidisciplinary Association for Psychedelic Studies

This MedLibrary.org supplementary page on Multidisciplinary Association for Psychedelic Studies is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:

Related Sponsors

BM Pharmacy Generic pharmaceuticals at unbeatable prices. Insomnia, men's health, hair health, pain control. bmpharmacy.com
Online Pharmacy Carisoprodol, tadalafil, sildenafil, vardenafil and more... xlpharmacy.com
MedBasket.com Discreet. Inexpensive. Fast shipping. Great selection. What more can we say? medbasket.com
Frugalmed 2000 reasons to shop with us first. frugalmed.com
Ads by Tiva

The Multidisciplinary Association for Psychedelic Studies (MAPS) is a U.S.-based non-profit organization that assists scientists to design, fund, obtain approval for and report on studies into the risks and benefits of psychedelic drugs (including MDMA, ibogaine and cannabis). MAPS' mission is to develop these drugs into FDA-approved prescription medicines, and to educate the public about their risks and benefits. MAPS has often been at odds with the National Institute on Drug Abuse (NIDA) and the Drug Enforcement Administration (DEA) in their efforts to research the medicinal purposes of cannabis. MAPS founder Rick Doblin claims that NIDA is "scared of the research" MAPS is performing.[1] MAPS has a $5 million, 5 year plan to conduct the research necessary to obtain FDA approval for MDMA-assisted psychotherapy as a treatment for post-traumatic stress disorder (PTSD). In addition to its research efforts, MAPS has recently published six books, and publishes a quarterly journal, the MAPS Bulletin. The organization was founded by Rick Doblin in 1986.

Achievements

Since 1995, MAPS has disbursed over three million dollars to research and educational projects and has:

  • Obtained FDA and IRB approval to study MDMA-assisted psychotherapy in the treatment of post-traumatic stress disorder (PTSD) in Charleston, SC with similar research projects now underway in Switzerland and Israel.
  • Sponsored efforts by Prof. Lyle Craker, Medicinal Plant Program, UMass Amherst Department of Plant and Soil Sciences, to obtain a license from the Drug Enforcement Administration for a marijuana production facility.
  • Sponsored pioneering analytical research into the effects of the marijuana vaporizer, leading to the first human study of marijuana vaporizers conducted by Dr. Donald Abrams, UC San Francisco.
  • Opened an FDA Drug Master File for MDMA. This is required before any drug can be researched in FDA-approved human studies.
  • Assisted Dr. Charles Grob to design, obtain approval for and fund the first FDA-approved study in the U.S. to administer MDMA to humans.
  • Assisted in the design and is funding the world's first government-approved scientific study of the therapeutic use of MDMA (Spain).
  • Sponsored studies to analyze the purity and potency of street samples of "Ecstasy" and medical marijuana.
  • Funded the successful efforts of Dr. Donald Abrams to obtain approval for the first human study in 15 years into the therapeutic use of marijuana, along with a $1 million grant from the National Institute on Drug Abuse.
  • Obtained Orphan Drug designation from the FDA for smoked marijuana in the treatment of AIDS Wasting Syndrome.
  • Funded the synthesis of psilocybin for the first FDA-approved study in twenty-five years to evaluate psilocybin in a patient population.
  • Supported long-term follow-up studies of pioneering research with LSD and psilocybin originally conducted in the 1950s and 1960s.

Currently, MAPS has been given a Schedule I license to conduct research with MDMA on veterans and survivors of physical or sexual assault who are suffering from post traumatic stress disorder, as well as with advanced-stage Cancer patients who are experiencing anxiety associated with this diagnosis, the first licenses the DEA has granted for MDMA psychotherapy research.

A clinical study of these treatment of cluster headaches using low doses of the tryptamine psilocybin (found in magic mushrooms) is being developed by researchers at Harvard Medical School, McLean Hospital in conjunction with MAPS.[2][3]

References

  1. ^ Greenberg, Gary (2005-11-01). "Respectable Reefer", Mother Jones. Retrieved on 2007-04-03. 
  2. ^ "Research into psilocybin and LSD as potential treatments for people with cluster headaches". LSD and Psilocybin Research. Multidisciplinary Association for Psychedelic Studies. Retrieved on 2006-09-22.
  3. ^ "Response of Cluster Headache to Psilocybin and LSD" Chapter 5 in "Psychedelic Medicine: New Evidence for Hallucinogens as Treatment" Michael Winkelman and Thomas B. Roberts (editors) (2007) Westport, CT: Praeger/Greenwood.

External links

 This article related to a non-profit organization is a stub. You can help Wikipedia by expanding it.
 This article about an organization in the United States is a stub. You can help Wikipedia by expanding it.
 This article related to psychedelics, dissociatives and deliriants is a stub. You can help Wikipedia by expanding it.

Wikipedia content modification information:

  • This page was last modified on 4 August 2008, at 23:00.

Wikipedia Authorship and Review

Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.

Wikipedia Usage Guidelines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Multidisciplinary Association for Psychedelic Studies".

The URL for this specific entry is:

All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.